<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546572</url>
  </required_header>
  <id_info>
    <org_study_id>6115A1-3005</org_study_id>
    <secondary_id>B1851024</secondary_id>
    <nct_id>NCT00546572</nct_id>
  </id_info>
  <brief_title>Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)</brief_title>
  <official_title>A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and immunogenicity of study vaccines 13vPnC
      and 23vPS in older, healthy subjects who have previously received a dose of 23vPS at least 5
      years ago. It will also evaluate the safety, tolerability and immunogenicity to a dose of
      13vPnC 1 year after the initial dose of study vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)</measure>
    <time_frame>1 month after Vax 1 / Year 0</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a â‰¥ 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0)</measure>
    <time_frame>Baseline, 1 month after Vax 1 / Year 0</time_frame>
    <description>OPA titer for the 6A serotype measured for at least a 4-fold increase from the prevaccination to postvaccination blood sample collection. Exact 2-sided CI (Clopper and Pearson) based upon the observed percentage of participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0)</measure>
    <time_frame>1 month after Vax 1 / Year 0</time_frame>
    <description>Antibody geometric mean titer as measured by OPA assay for the 6A pneumococcal serotype. Confidence intervals for the GMT are back transformation of a CI based on the Student t distribution for the mean logarithm of the titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)</measure>
    <time_frame>1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1</time_frame>
    <description>Antibody geometric mean titers as measured by OPA assays for the 13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)</measure>
    <time_frame>1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1</time_frame>
    <description>Antibody geometric mean titers as measured by OPA assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)</measure>
    <time_frame>1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1</time_frame>
    <description>Antibody geometric mean titer as measured by OPA assay for the 6A serotype. Confidence intervals (CI) for the GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">938</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives 13vPnC at year 0 and 13vPnC at year 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receives 23vPS at year 0 and 13vPnC at year 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13 valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23vPS</intervention_name>
    <description>0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female aged 70 years or older.

          -  Documented vaccination with 1 dose of 23vPS at least 5 years previous.

          -  Healthy.

        Exclusion Criteria:

          -  Receipt of more than one dose of 23vPS prior to enrollment.

          -  History of severe adverse reaction to a vaccine.

          -  Immunodeficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Downington</city>
        <state>Pennsylvania</state>
        <zip>19335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Grove City</city>
        <state>Pennsylvania</state>
        <zip>16127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Penndel</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Upper St. Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>998101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arlov</city>
        <zip>23234</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boden</city>
        <zip>96131</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Degeberga</city>
        <zip>29731</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gothenburg</city>
        <zip>40014</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Malmoe</city>
        <zip>21120</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Umea</city>
        <zip>90736</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6115A1-3005&amp;StudyName=Study%20Evaluating%20The%20Safety%2C%20Tolerability%20And%20Immunogenicity%20Of%20A%2013-Valent%20Pneumococcal%20Conjugate%20Vaccine%20%2813vPnC%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2007</study_first_submitted>
  <study_first_submitted_qc>October 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2007</study_first_posted>
  <results_first_submitted>April 29, 2011</results_first_submitted>
  <results_first_submitted_qc>April 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2011</results_first_posted>
  <last_update_submitted>July 12, 2011</last_update_submitted>
  <last_update_submitted_qc>July 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13vPnC / 13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliters (mL) dose intramuscularly (IM) at Year 0 (vaccination 1 [Vax 1]) and 13vPnC 0.5 mL IM at Year 1 (Vax 2)</description>
        </group>
        <group group_id="P2">
          <title>23vPS / 13vPnC</title>
          <description>23-valent pneumococcal polysaccharide conjugate vaccine (23vPS) 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL IM at Year 1 (Vax 2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Vax 1 / Year 0</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="464"/>
                <participants group_id="P2" count="474"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vax 1</title>
              <participants_list>
                <participants group_id="P1" count="463"/>
                <participants group_id="P2" count="473"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="391"/>
                <participants group_id="P2" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized, not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>6-Month Contact; withdraw before Vax 2</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Vax 2 / Year 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="391"/>
                <participants group_id="P2" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vax 2</title>
              <participants_list>
                <participants group_id="P1" count="391"/>
                <participants group_id="P2" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
                <participants group_id="P2" count="402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Vax 2; withdraw before 6-Month Contact</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)</description>
        </group>
        <group group_id="B2">
          <title>23vPS</title>
          <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="463"/>
            <count group_id="B2" value="473"/>
            <count group_id="B3" value="936"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.7" spread="4.6"/>
                    <measurement group_id="B2" value="76.7" spread="4.5"/>
                    <measurement group_id="B3" value="76.7" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>1 month after Vax 1 / Year 0</time_frame>
        <population>Evaluable Immunogenicity population: treatments as randomized at all expected doses, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable Immunogenicity population: treatments as randomized at all expected doses, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="68.4" upper_limit="95.9"/>
                    <measurement group_id="O2" value="55" lower_limit="46.2" upper_limit="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="47.7" upper_limit="62.9"/>
                    <measurement group_id="O2" value="49" lower_limit="42.9" upper_limit="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="545" lower_limit="441.9" upper_limit="672.3"/>
                    <measurement group_id="O2" value="203" lower_limit="157.1" upper_limit="262.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="59.7" upper_limit="86.6"/>
                    <measurement group_id="O2" value="36" lower_limit="29.5" upper_limit="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1261" lower_limit="1024.7" upper_limit="1552.6"/>
                    <measurement group_id="O2" value="417" lower_limit="330.5" upper_limit="526.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245" lower_limit="191.9" upper_limit="312.4"/>
                    <measurement group_id="O2" value="160" lower_limit="123.5" upper_limit="207.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181" lower_limit="138.0" upper_limit="237.0"/>
                    <measurement group_id="O2" value="90" lower_limit="67.8" upper_limit="119.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280" lower_limit="227.5" upper_limit="345.5"/>
                    <measurement group_id="O2" value="285" lower_limit="228.9" upper_limit="354.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="907" lower_limit="761.9" upper_limit="1080.1"/>
                    <measurement group_id="O2" value="481" lower_limit="385.1" upper_limit="600.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354" lower_limit="307.7" upper_limit="408.4"/>
                    <measurement group_id="O2" value="200" lower_limit="170.0" upper_limit="234.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333" lower_limit="273.2" upper_limit="404.8"/>
                    <measurement group_id="O2" value="214" lower_limit="174.3" upper_limit="262.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" lower_limit="126.0" upper_limit="198.6"/>
                    <measurement group_id="O2" value="43" lower_limit="34.2" upper_limit="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion). Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion). Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion). Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.93</ci_lower_limit>
            <ci_upper_limit>3.74</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion). Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.55</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion). Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.21</ci_lower_limit>
            <ci_upper_limit>4.13</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion). Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale. Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>2.97</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion). Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion). Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>2.50</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion). Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.43</ci_lower_limit>
            <ci_upper_limit>2.20</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion). Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion). Statistical significance demonstrated if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 1.</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.69</ci_lower_limit>
            <ci_upper_limit>5.09</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a â‰¥ 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0)</title>
        <description>OPA titer for the 6A serotype measured for at least a 4-fold increase from the prevaccination to postvaccination blood sample collection. Exact 2-sided CI (Clopper and Pearson) based upon the observed percentage of participants.</description>
        <time_frame>Baseline, 1 month after Vax 1 / Year 0</time_frame>
        <population>Evaluable Immunogenicity population. N=number of participants with a determinate antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a â‰¥ 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0)</title>
          <description>OPA titer for the 6A serotype measured for at least a 4-fold increase from the prevaccination to postvaccination blood sample collection. Exact 2-sided CI (Clopper and Pearson) based upon the observed percentage of participants.</description>
          <population>Evaluable Immunogenicity population. N=number of participants with a determinate antibody titer to the given serotype.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" lower_limit="66.4" upper_limit="75.4"/>
                    <measurement group_id="O2" value="27.3" lower_limit="23.0" upper_limit="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: difference in proportions, 13vPnC - 23vPS, expressed as a percentage.
Statistical significance was shown if the lower limit of the 95% CI for the difference in proportions (13vPnC â€“ 23vPS) was &gt; 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>43.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.4</ci_lower_limit>
            <ci_upper_limit>49.9</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI (based on Chan and Zhang) for the difference in proportions, 13vPnC â€“ 23vPS expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0)</title>
        <description>Antibody geometric mean titer as measured by OPA assay for the 6A pneumococcal serotype. Confidence intervals for the GMT are back transformation of a CI based on the Student t distribution for the mean logarithm of the titer.</description>
        <time_frame>1 month after Vax 1 / Year 0</time_frame>
        <population>Evaluable Immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0)</title>
          <description>Antibody geometric mean titer as measured by OPA assay for the 6A pneumococcal serotype. Confidence intervals for the GMT are back transformation of a CI based on the Student t distribution for the mean logarithm of the titer.</description>
          <population>Evaluable Immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="903" lower_limit="726.7" upper_limit="1121.3"/>
                    <measurement group_id="O2" value="94" lower_limit="74.1" upper_limit="118.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: ratio of GMT (13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.
Statistical significance was demonstrated if the lower limit of the 2-sided 95% confidence interval for the geometric mean ratio was &gt;2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>9.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.00</ci_lower_limit>
            <ci_upper_limit>13.26</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC â€“ 23vPS).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)</title>
        <description>Antibody geometric mean titers as measured by OPA assays for the 13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1</time_frame>
        <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the given serotype at both the postvaccination 1 and postvaccination 2 blood draws.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)</title>
          <description>Antibody geometric mean titers as measured by OPA assays for the 13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the given serotype at both the postvaccination 1 and postvaccination 2 blood draws.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="65.3" upper_limit="94.6"/>
                    <measurement group_id="O2" value="76" lower_limit="64.8" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="47.2" upper_limit="64.0"/>
                    <measurement group_id="O2" value="55" lower_limit="48.4" upper_limit="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614" lower_limit="489.8" upper_limit="768.8"/>
                    <measurement group_id="O2" value="487" lower_limit="393.9" upper_limit="603.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="56.2" upper_limit="84.2"/>
                    <measurement group_id="O2" value="57" lower_limit="46.9" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="971" lower_limit="771.0" upper_limit="1222.1"/>
                    <measurement group_id="O2" value="1169" lower_limit="974.0" upper_limit="1403.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1358" lower_limit="1085.4" upper_limit="1700.2"/>
                    <measurement group_id="O2" value="1590" lower_limit="1316.9" upper_limit="1919.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222" lower_limit="170.2" upper_limit="290.2"/>
                    <measurement group_id="O2" value="180" lower_limit="138.1" upper_limit="233.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187" lower_limit="139.3" upper_limit="250.4"/>
                    <measurement group_id="O2" value="166" lower_limit="124.2" upper_limit="220.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265" lower_limit="209.9" upper_limit="333.6"/>
                    <measurement group_id="O2" value="241" lower_limit="194.4" upper_limit="299.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="918" lower_limit="763.4" upper_limit="1104.3"/>
                    <measurement group_id="O2" value="1003" lower_limit="850.2" upper_limit="1182.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349" lower_limit="299.7" upper_limit="405.5"/>
                    <measurement group_id="O2" value="341" lower_limit="297.2" upper_limit="390.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329" lower_limit="265.6" upper_limit="408.6"/>
                    <measurement group_id="O2" value="322" lower_limit="266.3" upper_limit="389.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" lower_limit="130.9" upper_limit="213.0"/>
                    <measurement group_id="O2" value="309" lower_limit="251.6" upper_limit="380.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: geometric mean fold rise (GMFR) [(13vPnC / 13vPnC) / (13vPnC)] calculated using all participants with available data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 95% confidence interval for the back-transformed GMFR was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.60</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
            <estimate_desc>Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)</title>
        <description>Antibody geometric mean titers as measured by OPA assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1</time_frame>
        <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)</title>
          <description>Antibody geometric mean titers as measured by OPA assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
          <units>geometric mean titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="370"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="64.9" upper_limit="89.5"/>
                    <measurement group_id="O2" value="55" lower_limit="46.2" upper_limit="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="47.9" upper_limit="62.0"/>
                    <measurement group_id="O2" value="49" lower_limit="42.9" upper_limit="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="472" lower_limit="383.5" upper_limit="580.2"/>
                    <measurement group_id="O2" value="203" lower_limit="157.1" upper_limit="262.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="46.6" upper_limit="67.7"/>
                    <measurement group_id="O2" value="36" lower_limit="29.5" upper_limit="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1565" lower_limit="1306.1" upper_limit="1875.9"/>
                    <measurement group_id="O2" value="417" lower_limit="330.5" upper_limit="526.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185" lower_limit="142.9" upper_limit="239.7"/>
                    <measurement group_id="O2" value="160" lower_limit="123.5" upper_limit="207.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" lower_limit="119.5" upper_limit="209.5"/>
                    <measurement group_id="O2" value="90" lower_limit="67.8" upper_limit="119.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238" lower_limit="192.3" upper_limit="293.8"/>
                    <measurement group_id="O2" value="285" lower_limit="228.9" upper_limit="354.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="975" lower_limit="829.0" upper_limit="1147.3"/>
                    <measurement group_id="O2" value="481" lower_limit="385.1" upper_limit="600.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339" lower_limit="296.4" upper_limit="386.9"/>
                    <measurement group_id="O2" value="200" lower_limit="170.0" upper_limit="234.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311" lower_limit="257.1" upper_limit="375.9"/>
                    <measurement group_id="O2" value="214" lower_limit="174.3" upper_limit="262.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310" lower_limit="254.1" upper_limit="378.0"/>
                    <measurement group_id="O2" value="43" lower_limit="34.2" upper_limit="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.66</ci_lower_limit>
            <ci_upper_limit>3.25</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.78</ci_lower_limit>
            <ci_upper_limit>5.07</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.53</ci_lower_limit>
            <ci_upper_limit>2.69</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.37</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority declared if the lower limit of the 2-sided 95 % confidence interval for the geometric mean ratio (GMR) was &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.36</ci_lower_limit>
            <ci_upper_limit>9.82</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)</title>
        <description>Antibody geometric mean titer as measured by OPA assay for the 6A serotype. Confidence intervals (CI) for the GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titer.</description>
        <time_frame>1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1</time_frame>
        <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)</title>
          <description>Antibody geometric mean titer as measured by OPA assay for the 6A serotype. Confidence intervals (CI) for the GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titer.</description>
          <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1134" lower_limit="943.6" upper_limit="1363.7"/>
                    <measurement group_id="O2" value="94" lower_limit="74.1" upper_limit="118.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: ratio of GMT (13vPnC / 13vPnC to 23vPS) calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.
Statistical significance was demonstrated if the lower limit of the 2-sided 95% confidence interval for the geometric mean ratio was &gt;2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>12.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.92</ci_lower_limit>
            <ci_upper_limit>16.44</ci_upper_limit>
            <estimate_desc>Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC / 13vPnC )â€“ (23vPS)].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)</title>
        <description>Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)</description>
        <time_frame>Days 1 through 14 / Year 0</time_frame>
        <population>Safety population is all participants who receive at least 1 dose of study vaccine. N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC and 23vPS (Vax 1). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)</title>
          <description>Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)</description>
          <population>Safety population is all participants who receive at least 1 dose of study vaccine. N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC and 23vPS (Vax 1). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="370"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=306, 324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8"/>
                    <measurement group_id="O2" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=304, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=301, 314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=299, 310)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=307, 333)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=305, 315)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=299, 323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=297, 310)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=362, 383)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7"/>
                    <measurement group_id="O2" value="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=359, 377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1"/>
                    <measurement group_id="O2" value="54.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=306, 330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=299, 306)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=313, 326)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=312, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n=297, 303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=298, 305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Redness: any; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-11.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.3</ci_lower_limit>
            <ci_upper_limit>-5.6</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Redness: mild; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.129</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Redness: moderate; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>-2.3</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Redness: severe; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Swelling: any; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-12.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.5</ci_lower_limit>
            <ci_upper_limit>-7.0</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Swelling: mild; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Swelling: moderate; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-9.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>-5.1</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Swelling: severe; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>-2.7</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain: any; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>Chan &amp; Zhang</param_type>
            <param_value>-6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.0</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain: mild; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.284</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain: moderate; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-16.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.7</ci_lower_limit>
            <ci_upper_limit>-10.6</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain: severe; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.539</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Limitation of arm movement: any; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-17.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.1</ci_lower_limit>
            <ci_upper_limit>-11.1</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Limitation of arm movement: mild; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-14.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.8</ci_lower_limit>
            <ci_upper_limit>-9.0</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Limitation of arm movement: moderate; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Limitation of arm movement: severe; difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Limitation of arm movement: any; differe</method>
            <param_type>difference in proportions</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</title>
        <description>Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)</description>
        <time_frame>Days 1 through 14 / Year 0, Days 1 through 14 / Year 1</time_frame>
        <population>Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</title>
          <description>Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)</description>
          <population>Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=185, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=182, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=182, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=179, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=185, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=182, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=179, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=177, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=258, 258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0"/>
                    <measurement group_id="O2" value="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=251, 251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0"/>
                    <measurement group_id="O2" value="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=187, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=179, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=195, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=194, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n=178, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=178, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</title>
        <description>Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)</description>
        <time_frame>Days 1 through 14 / Year 0, Days 1 through 14 / Year 1</time_frame>
        <population>Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 23vPS (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>23vPS</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</title>
          <description>Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)</description>
          <population>Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 23vPS (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=324, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=311, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=314, 231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=310, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=333, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=315, 234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=323, 229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=310, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=383, 297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5"/>
                    <measurement group_id="O2" value="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=377, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1"/>
                    <measurement group_id="O2" value="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=330, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6"/>
                    <measurement group_id="O2" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=306, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=326, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=322, 245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                    <measurement group_id="O2" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n=303, 228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=305, 228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )</title>
        <description>Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)</description>
        <time_frame>Days 1 through 14 / Year 1</time_frame>
        <population>Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC / 13vPnC and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
          <group group_id="O2">
            <title>23vPS / 13vPnC</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )</title>
          <description>Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)</description>
          <population>Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC / 13vPnC and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=236, 228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O2" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=233, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=231, 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=227, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=236, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=234, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=229, 229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=227, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=297, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2"/>
                    <measurement group_id="O2" value="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=291, 297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3"/>
                    <measurement group_id="O2" value="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=239, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=226, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=247, 251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                    <measurement group_id="O2" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=245, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n=228, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=228, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)</title>
        <description>Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)</description>
        <time_frame>Days 1 through 14 / Year 0, Days 1 through 14 / Year 1</time_frame>
        <population>Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>23vPS / 13vPnC</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)</title>
          <description>Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)</description>
          <population>Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="370"/>
                <count group_id="O2" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=306, 228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8"/>
                    <measurement group_id="O2" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=304, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=301, 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=299, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=307, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=305, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=299, 229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=297, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=362, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7"/>
                    <measurement group_id="O2" value="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=359, 297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1"/>
                    <measurement group_id="O2" value="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=306, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=299, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=313, 251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=312, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n=297, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=298, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)</title>
        <description>Systemic events reported using electronic diary. Fever scaled as Any (â‰¥38 degrees Celsius [C]); Mild (â‰¥38 but &lt;38.5 degrees C); Moderate (â‰¥38.5 but &lt;39 degrees C); Severe (â‰¥39 but â‰¤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).</description>
        <time_frame>Days 1 through 14 / Year 0</time_frame>
        <population>Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC and 23vPS (Year 0). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)</title>
          <description>Systemic events reported using electronic diary. Fever scaled as Any (â‰¥38 degrees Celsius [C]); Mild (â‰¥38 but &lt;38.5 degrees C); Moderate (â‰¥38.5 but &lt;39 degrees C); Severe (â‰¥39 but â‰¤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).</description>
          <population>Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC and 23vPS (Year 0). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any â‰¥38 degrees C (n=299, 309)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild â‰¥38 but &lt;38.5 degrees C (n=299, 303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate â‰¥38.5 but &lt;39 degrees C(n=297,301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe â‰¥39 but â‰¤40 degrees C (n=297, 301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potentially life-threatening &gt;40C (n=297, 307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=350, 367)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0"/>
                    <measurement group_id="O2" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=329, 331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7"/>
                    <measurement group_id="O2" value="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=305, 312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=303, 323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=300, 304)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=317, 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=345, 358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=320, 334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=310, 323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=310, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>New generalized muscle pain: difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.2</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Aggravated generalized muscle pain: difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Chan &amp; Zhang</method>
            <param_type>difference in proportions</param_type>
            <param_value>-6.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.6</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
            <estimate_desc>Exact 2-sided confidence interval and corresponding p-value (based on Chan &amp; Zhang) for the difference in proportions, [13vPnC] â€“ [23vPS], expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</title>
        <description>Systemic events reported using electronic diary. Fever scaled as Any (â‰¥38 degrees Celsius [C]); Mild (â‰¥38 but &lt;38.5 degrees C); Moderate (â‰¥38.5 but &lt;39 degrees C); Severe (â‰¥39 but â‰¤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).</description>
        <time_frame>Days 1 through 14 / Year 0, Days 1 through 14 / Year 1</time_frame>
        <population>Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</title>
          <description>Systemic events reported using electronic diary. Fever scaled as Any (â‰¥38 degrees Celsius [C]); Mild (â‰¥38 but &lt;38.5 degrees C); Moderate (â‰¥38.5 but &lt;39 degrees C); Severe (â‰¥39 but â‰¤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).</description>
          <population>Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any â‰¥38 degrees C (n=179, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild â‰¥38 but &lt;38.5 degrees C (n=179, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate â‰¥38.5 but &lt;39 degrees C(n=177,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe â‰¥39 but â‰¤40 degrees C (n=177, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potentially life-threatening &gt;40C (n=177, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=215, 215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=200, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=182, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=183, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=178, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=219, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                    <measurement group_id="O2" value="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=198, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=187, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                    <measurement group_id="O2" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=188, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                    <measurement group_id="O2" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</title>
        <description>Systemic events reported using electronic diary. Fever scaled as Any (â‰¥38 degrees Celsius [C]); Mild (â‰¥38 but &lt;38.5 degrees C); Moderate (â‰¥38.5 but &lt;39 degrees C); Severe (â‰¥39 but â‰¤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).</description>
        <time_frame>Days 1 through 14 / Year 0, Days 1 through 14 / Year 1</time_frame>
        <population>Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 23vPS (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>23vPS</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</title>
          <description>Systemic events reported using electronic diary. Fever scaled as Any (â‰¥38 degrees Celsius [C]); Mild (â‰¥38 but &lt;38.5 degrees C); Moderate (â‰¥38.5 but &lt;39 degrees C); Severe (â‰¥39 but â‰¤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).</description>
          <population>Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 23vPS (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any â‰¥38 degrees C (n=309, 229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild â‰¥38 but &lt;38.5 degrees C (n=303, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate â‰¥38.5 but &lt;39 degrees C(n=301,227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe â‰¥39 but â‰¤40 degrees C (n=301, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potentially life-threatening &gt;40C (n=307, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=367, 255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3"/>
                    <measurement group_id="O2" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=331, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0"/>
                    <measurement group_id="O2" value="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=312, 234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=323, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=304, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=313, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=358, 260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=334, 245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                    <measurement group_id="O2" value="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=323, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=322, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)</title>
        <description>Systemic events reported using electronic diary. Fever scaled as Any (â‰¥38 degrees Celsius [C]); Mild (â‰¥38 but &lt;38.5 degrees C); Moderate (â‰¥38.5 but &lt;39 degrees C); Severe (â‰¥39 but â‰¤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).</description>
        <time_frame>Days 1 through 14 / Year 1</time_frame>
        <population>Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC / 13vPnC and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
          <group group_id="O2">
            <title>23vPS / 13vPnC</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax )</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)</title>
          <description>Systemic events reported using electronic diary. Fever scaled as Any (â‰¥38 degrees Celsius [C]); Mild (â‰¥38 but &lt;38.5 degrees C); Moderate (â‰¥38.5 but &lt;39 degrees C); Severe (â‰¥39 but â‰¤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).</description>
          <population>Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC / 13vPnC and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any â‰¥38 degrees C (n=229, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild â‰¥38 but &lt;38.5 degrees C (n=227, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate â‰¥38.5 but &lt;39 degrees C(n=227,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe â‰¥39 but â‰¤40 degrees C (n=226, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potentially life-threatening &gt;40C (n=227, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=255, 265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=246, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=234, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=232, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=226, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=237, 230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=260, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=245, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=238, 234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=239, 231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)</title>
        <description>Systemic events reported using electronic diary. Fever scaled as Any (â‰¥38 degrees Celsius [C]); Mild (â‰¥38 but &lt;38.5 degrees C); Moderate (â‰¥38.5 but &lt;39 degrees C); Severe (â‰¥39 but â‰¤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).</description>
        <time_frame>Days 1 through 14 / Year 0, Days 1 through 14 / Year 1</time_frame>
        <population>Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)</description>
          </group>
          <group group_id="O2">
            <title>23vPS / 13vPnC</title>
            <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)</title>
          <description>Systemic events reported using electronic diary. Fever scaled as Any (â‰¥38 degrees Celsius [C]); Mild (â‰¥38 but &lt;38.5 degrees C); Moderate (â‰¥38.5 but &lt;39 degrees C); Severe (â‰¥39 but â‰¤40 degrees C); Potentially life-threatening (&gt;40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).</description>
          <population>Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any â‰¥38 degrees C (n=299, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild â‰¥38 but &lt;38.5 degrees C (n=299, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate â‰¥38.5 but &lt;39 degrees C(n=297,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe â‰¥39 but â‰¤40 degrees C (n=297, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potentially life-threatening &gt;40C (n=297, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=350, 265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0"/>
                    <measurement group_id="O2" value="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=329, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7"/>
                    <measurement group_id="O2" value="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=305, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=303, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=300, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=317, 230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=345, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=320, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=310, 234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=310, 231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.</time_frame>
      <desc>Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC (Vax 1 / Year 0) 1 Month After Vaccination</title>
          <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=66; systematic (solicited) Local Reactions N=209; systematic (solicited) Systemic Events N=234.</description>
        </group>
        <group group_id="E2">
          <title>23vPS (Vax 1 / Year 0) 1 Month After Vaccination</title>
          <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=83; systematic (solicited) Local Reactions N=248; systematic (solicited) Systemic Events N=275.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC 6-M FU (Vax 1 / Year 0)</title>
          <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1); events assessed at 6-Month Follow-up visit (6-M FU) (Vax 1 / Year 0) telephone visit to report new events.</description>
        </group>
        <group group_id="E4">
          <title>23vPS 6-M FU (Vax 1 / Year 0)</title>
          <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1); events assessed at 6-M FU (Vax 1 / Year 0) telephone visit to report new events.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination</title>
          <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=69; systematic (solicited) Local Reactions N=191; systematic (solicited) Systemic Events N=161.</description>
        </group>
        <group group_id="E6">
          <title>23vPS / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination</title>
          <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=62; systematic (solicited) Local Reactions N=189; systematic (solicited) Systemic Events N=174.</description>
        </group>
        <group group_id="E7">
          <title>13vPnC / 13vPnC 6-M FU (Vax 2 / Year 1)</title>
          <description>13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2) ; events assessed at 6-M FU (Vax 2 / Year 1) telephone visit to report new events.</description>
        </group>
        <group group_id="E8">
          <title>23vPS / 13vPnC 6-M FU (Vax 2 / Year 1)</title>
          <description>23vPS 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose at Year 1 (Vax 2); events assessed at 6-M FU (Vax 2 / Year 1) telephone visit to report new events.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Colonic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Post procedural pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="234" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="275" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="191" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="189" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="30" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Presbyopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Lip pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gastric mucosal lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Injection site movement impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Vaccination site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Any) â‰¥ 38 degrees Celsius (C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Mild) â‰¥ 38 degrees but &lt; 38.5 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Moderate) â‰¥ 38.5 degrees but &lt; 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Severe) â‰¥ 39 degrees but â‰¤ 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Potentially life threatening) &gt; 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="367"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="73" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="91" subjects_at_risk="265"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="246"/>
                <counts group_id="E6" subjects_affected="56" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="234"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="233"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="237"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="230"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="345"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="260"/>
                <counts group_id="E6" subjects_affected="92" subjects_at_risk="263"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="52" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="238"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="234"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="322"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="231"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Any) â‰¥ 38 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Mild) â‰¥ 38 degrees but &lt; 38.5 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fever (Moderate) â‰¥ 38.5 degrees but &lt; 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Severe) â‰¥ 39 degrees but â‰¤ 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Potentially life threatening) &gt; 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="215"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="182"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="190"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="78" subjects_at_risk="219"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="188"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Wound infecton</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Factured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Biopsy skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Blood parathyroid hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Type I diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pelvic deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Anosmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hemianopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Narcolepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Renal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Renal artery arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Breast calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Nasal septum perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Campbell de Morgan spots</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Cutis laxa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Eczema nummular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Lichenoid keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Skin wrinkling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pruritus generalising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="236"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="228"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="311"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="233"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="226"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="231"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="310"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="307"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="236"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="241"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="234"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="236"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="310"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="224" subjects_at_risk="383"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="173" subjects_at_risk="297"/>
                <counts group_id="E6" subjects_affected="171" subjects_at_risk="302"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="377"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="158" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="159" subjects_at_risk="297"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="236"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="306"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="50" subjects_at_risk="251"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="322"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="47" subjects_at_risk="249"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS (Vax 1 / Year 0); 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2/ Year 1)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="305"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="182"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="182"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="182"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="148" subjects_at_risk="258"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="251"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="136" subjects_at_risk="251"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Aortic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Vasoconstriction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Wyeth has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

